We report on two Korean patients who developed pure red-cell aplasia (PRCA) due to anti-erythropoietin (EPO) antibodies. The first patient became refractory to EPO treatment after a good response for an initial 26 months. Anti-EPO antibodies were detected by enzyme linked immunosorbent assay (ELISA) and by radioimmunoprecipitation (RIPA), and these were found to inhibit erythroid colony formation by in vitro bioassay. In the second patient, the anemia became aggravated, accompanied by thrombocytopenia and wheals appeared at the EPO injection site 3 months after the initiation of subcutaneous EPO treatment. Anti-EPO antibodies were detected by ELISA, and the patient showed a partial response to the second corticosteroid treatment course. Our cases demonstrate that PRCA due to anti-EPO antibodies becomes an important issue in Asians as well as in Caucasians.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Study on Internal Standards Applicable to the Detection of Recombinant Erythropoietin.
Drug Test Anal
December 2024
Beijing Anti-Doping Laboratory, Beijing Sport University, Beijing, China.
Article Synopsis
- The discovery of the c.577del variant in the EPO gene has complicated testing for recombinant erythropoietin (rEPO), making detection more challenging.
- Researchers developed a new confirmation method that combines reverse-normal immunopurification, western blotting (WB), and SAR-PAGE to effectively identify both the EPO variant (VAR-EPO) and rEPO using specific antibodies.
- An internal standard (IS) made from VAR-EPO modified with polyethylene glycol (PEG) was created and shown to effectively monitor rEPO detection in urine samples, ensuring reliable doping analysis results.
Article Synopsis
- - The case report highlights a 48-year-old woman with chronic kidney disease who developed pure red cell aplasia (PRCA) due to anti-erythropoietin (EPO) antibodies after receiving EPO injections for anemia.
- - Following a severe drop in her hemoglobin levels, she was treated with desidustat, a new oral medication that improved her hemoglobin significantly while being less likely to induce an immune response.
- - This case emphasizes the importance of quick diagnosis and the potential of desidustat as a safer alternative for treating anemia in patients, showcasing advancements in treatment within the context of the first reported case in India.
Positive response of a hemodialysis patient with pure red cell aplasia on recombinant human erythropoietin therapy to cyclosporine and Roxadustat.
CEN Case Rep
December 2024
Department of Nephrology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Article Synopsis
- Recombinant human erythropoietin (rHuEPO) is used to treat anemia in chronic kidney disease but can lead to a rare condition called EPO-induced Pure Red Cell Aplasia (PRCA), which causes severe anemia and requires stopping EPO therapy.
- In a reported case, a hemodialysis patient developed PRCA despite testing negative for anti-EPO antibodies, and treatment was successfully managed with cyclosporine and maintained using Roxadustat.
- The case highlights the clinical signs of EPO-induced PRCA, the limitations of the antibody assay for diagnosis, and various treatment strategies for managing the condition.
Serum anti-erythropoietin antibodies among pregnant women with Plasmodium falciparum malaria and anaemia: A case-control study in northern Ghana.
PLoS One
April 2023
Department of Medical Laboratory Sciences, Faculty of Health Science and Technology, Ebonyi State University, Abakaliki, Nigeria.
Background: Anaemia in pregnancy is common in underdeveloped countries, and malaria remains the predominant cause of the condition in Ghana. Anti-erythropoietin (anti-EPO) antibody production may be implicated in the pathogenesis of Plasmodium falciparum malaria-related anaemia in pregnancy. This study ascertained the prevalence of anti-EPO antibody production and evaluated the antibodies' relationship with Plasmodium falciparum malaria and malaria-related anaemia in pregnancy.
View Article and Find Full Text PDFCase report: Dynamic antibody monitoring in a case of anti-recombinant human erythropoietin-mediated pure red cell aplasia with prolonged course after kidney transplantation.
Front Immunol
December 2022
Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Anti-erythropoietin (anti-EPO) antibody-mediated pure red cell aplasia (PRCA) is a rarely seen disease. Anti-EPO antibodies were mostly found in patients with chronic kidney disease who received recombinant human erythropoietin (rHuEPO) injections subcutaneously. The treatment against anti-EPO antibody-mediated PRCA included discontinuation of rHuEPO, immunosuppressive agents, intravenous immunoglobulin, plasmapheresis, or kidney transplantation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!